Illumina Accelerator Invests in Second Class of Genomics Startups from US and Europe
August 05 2015 - 6:30AM
Business Wire
Startups from Spain, Oregon, and California to
advance breakthrough applications
Illumina, Inc. (NASDAQ:ILMN) today announced Illumina
Accelerator—the world’s first business accelerator focused solely
on creating an innovation ecosystem for the genomics industry—has
selected three new startups for its second funding cycle. Selected
from a competitive pool of highly qualified applicants, the new
startups from across the globe are spurring genomics innovation in
healthcare, agriculture, and the winemaking industry.
“We are delighted to invite such a promising group of
cutting-edge startups to Illumina Accelerator,” said Illumina
Senior Vice President and Chief Technology Officer, Mostafa
Ronaghi, Ph.D. “Their ability to build innovative solutions to
shape the future of genomics inspires us, and we’re thrilled to
provide them with tools and resources to build a successful
future.”
The selected startups for the spring 2015 funding cycle are:
- PathoGn, Inc. is an infectious
disease platform company based in California
using genomics and machine learning to build pathogen
diagnostics and disease forecasting products for agricultural
applications.
- Biome Makers Inc. is a
microbiome company founded by The Wine Guys, from Castile and Leon,
Spain, introducing advanced genomics in the wine sector to
transform the quality standards of vinification.
- Urology Diagnostics
Incorporated is a genomics company from Oregon developing
noninvasive urine sequencing diagnostics for screening and
monitoring cancer.
Each startup will receive seed investment, a subscription to
Illumina’s NextBio translational genomics database, access to match
funding through the $40 million Illumina Accelerator Boost Capital,
and Illumina’s sequencing systems and reagents. In addition,
startups accepted into Illumina Accelerator will gain access to
business guidance and fully operational lab space in the San
Francisco Bay Area during the six-month funding cycle.
“We look forward to building upon the successes of our first
graduates—Encoded Genomics, Inc., EpiBiome, Inc., and Xcell
Biosciences, Inc.—by helping our second group of startups also
create significant value, generate terabases of sequencing data,
and advance their genomics applications,” said Amanda Cashin,
Ph.D., who leads Illumina Accelerator.
Illumina Accelerator strives to catalyze genomics innovation in
the broader startup community. It aims to advance genomics by
lowering the barrier to entry and expedite the time to market for
entrepreneurs and early-stage companies that are working on
scientifically and commercially promising next-generation
sequencing applications. Startups are invited to join Illumina
Accelerator twice a year.
Applications for the Illumina Accelerator Fall 2015 funding
cycle are due by September 1, 2015. To apply, visit
www.illumina.com/accelerator.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150805005343/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Mina Nicoletti,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024